Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$NTLA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.80 up 18.37% YoY • Reported revenue of $7.66M down -46.23% YoY • Intellia Therapeutics expects FDA acceptance of its biologics license application for lonvo-z in the second half of 2026 and plans to launch lonvo-z commercially in the first half of 2027.
1

Price since post

Full Details

Advertisement|Remove ads.